CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure Intravascular Ultrasound to Guide Left Main Stem Intervention: A Sub-Study of the NOBLE Trial The year in cardiovascular medicine 2020: heart failure and cardiomyopathies Atrial Fibrillation and the Prognostic Performance of Biomarkers in Heart Failure Feasibility of Coronary Access and Aortic Valve Reintervention in Low-Risk TAVR Patients Impact of plaque components on no-reflow phenomenon after stent deployment in patients with acute coronary syndrome: a virtual histology-intravascular ultrasound analysis Nitrosative stress drives heart failure with preserved ejection fraction Clinical trial design and rationale of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) investigational device exemption clinical study protocol Unexpectedly Low Natriuretic Peptide Levels in Patients With Heart Failure A three-vessel virtual histology intravascular ultrasound analysis of frequency and distribution of thin-cap fibroatheromas in patients with acute coronary syndrome or stable angina pectoris

Original ResearchVolume 75, Issue 11, March 2020

JOURNAL:J Am Coll Cardiol. Article Link

Contrast-Associated Acute Kidney Injury and Serious Adverse Outcomes Following Angiography

SD Weisbord, PM Palevsky, the PRESERVE Trial Investigators et al. Keywords: angiography; contrast-associated acute kidney injury; mediation; outcomes

ABSTRACT

 

BACKGROUND - Contrast-associated acute kidney injury (CA-AKI) associates with an increased relative risk for serious adverse outcomes. However, the magnitude of this risk and the incidence of clinically significant CA-AKI derived from analyses of large cohorts with prospective assessment of CA-AKI and subsequent outcomes are unknown.

 

OBJECTIVES  - This study sought to characterize the relative risk for and incidence of serious adverse outcomes following the development of CA-AKI and to explore whether CA-AKI mediates the association of pre-angiography estimated glomerular filtration rate with adverse outcomes.

 

METHODS - Among 4,418 participants in the PRESERVE (Prevention of Serious Adverse Outcomes Following Angiography) trial with comprehensive baseline and outcome data, we assessed whether CA-AKI was associated with the 90-day outcome comprising death, need for dialysis, or persistent impairment in kidney function. We calculated the incidence of clinically significant CA-AKI (i.e., proportion of patients who developed CA-AKI and the 90-day outcome) and examined whether CA-AKI was a mediator of the association of baseline kidney function with the 90-day outcome.

 

RESULTS - CA-AKI was associated with an increased relative risk for 90-day death, need for dialysis, or persistent kidney impairment (odds ratio: 3.93; 95% confidence interval: 2.82 to 5.49; p < 0.0001). The incidence of clinically significant CA-AKI was 1.2% (53 of 4,418 patients). CA-AKI was not a mediator of the association of pre-angiography estimated glomerular filtration rate with the primary outcome.

 

CONCLUSIONS - CA-AKI was associated with an increased relative risk for 90-day death, need for dialysis, or persistent kidney impairment (odds ratio: 3.93; 95% confidence interval: 2.82 to 5.49; p < 0.0001). The incidence of clinically significant CA-AKI was 1.2% (53 of 4,418 patients). CA-AKI was not a mediator of the association of pre-angiography estimated glomerular filtration rate with the primary outcome.